Karolina has over eight years’ experience in building healthcare companies within the Cambridge Cluster. She has played a pivotal role in securing over £8.5 million for a number of British early-stage ventures (pre-seed and seed stage) from a stellar syndicate of investors (business angels and VCs). Karolina completed a PhD in Biophysics at the University of Cambridge and carried out her Postdoctoral work at AstraZeneca.
Reason for joining the NGWC:
“I am delighted to join the Ovarian Cancer Action's Next Generation Collective to support the organisation in fundraising and building awareness of women’s health. Research charities play an essential role in the UK life sciences ecosystem, and it is crucial to support them, especially now during the pandemic. In the last 15 years, Ovarian Cancer Action has channelled £12.3 million of funding into research projects. I feel very privileged to join the board this year to support this charity's fundraising for scientific research to deliver treatment and healthcare solutions faster to patients. In the UK, one woman dies every two hours from ovarian cancer, and it is critical that we address this.”